Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy

被引:30
作者
Gotoh, A
Kawakami, Y
Akahane, T
Akamatsu, T
Shimizu, T
Kiyosawa, K
Katsuyama, T
机构
[1] SHINSHU UNIV,SCH ALLIED MED SCI,DEPT MED TECHNOL,DIV CLIN MICROBIOL,MATSUMOTO,NAGANO 390,JAPAN
[2] SHINSHU UNIV HOSP,DEPT ENDOSCOPY,MATSUMOTO,NAGANO 390,JAPAN
[3] SHINSHU UNIV HOSP,CENT CLIN LABS,MATSUMOTO,NAGANO 390,JAPAN
关键词
Helicobacter pylori; susceptibility; eradication therapy;
D O I
10.1111/j.1348-0421.1997.tb01166.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although chemotherapy has been documented to be effective in the treatment of Helicobacter pylori-associated gastritis and gastroduodenal ulcers, some cases are known to have been unsuccessful in the attempt to eradicate this species. In this study, we examined the relation between the susceptibility of H. pylori isolates and the efficacy of chemotherapy. We utilized the modified agar plate dilution method to determine the minimum inhibitory concentrations (MICs) of 63 H. pylori strains isolated before treatment with several drugs routinely used during eradication chemotherapy. Among the drugs tested, amoxicillin (AMPC) and clarithromycin (CAM) demonstrated high degrees of activity with MIC(90), 0.39 and 0.2 mu g/ml, respectively. No highly resistant strain against AMPC was detected among the strains examined, while for CAM and metronidazole (MTZ), 9.5% and 7.9% of the strains, respectively, were resistant before treatment. It should be noted that all of the MICs of the strains from patients with successful therapy were lower than those from patients with unsuccessful therapy. These findings indicate that susceptibility tests should be carried out prior to the commencement of drug administration in order to provide safer and more effective chemotherapy.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 24 条
[1]   HISTOCHEMICAL-STUDY OF HELICOBACTER-PYLORI AND SURFACE MUCOUS GEL LAYER IN VARIOUS GASTRIC-LESIONS [J].
AKAMATSU, T ;
OTA, H ;
SHIMIZU, T ;
MATSUZAWA, K ;
FUJIMORI, Y ;
NAKAMURA, N ;
KIYOSAWA, K ;
KATSUYAMA, T .
ACTA HISTOCHEMICA ET CYTOCHEMICA, 1995, 28 (02) :181-185
[2]   HELICOBACTER-PYLORI THERAPY - EFFECT ON PEPTIC-ULCER DISEASE [J].
AXON, ATR .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1991, 6 (02) :131-137
[3]   SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI [J].
BAZZOLI, F ;
ZAGARI, RM ;
FOSSI, S ;
POZZATO, P ;
ALAMPI, G ;
SIMONI, P ;
SOTTILI, S ;
RODA, A ;
RODA, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) :773-777
[4]   METRONIDAZOLE-RESISTANT HELICOBACTER-PYLORI [J].
BECX, MCJM ;
JANSSEN, AJHM ;
CLASENER, HAL ;
DEKONING, RW .
LANCET, 1990, 335 (8688) :539-540
[5]  
CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716
[6]   LOCAL GASTRIC AND SERUM AMOXICILLIN CONCENTRATIONS AFTER DIFFERENT ORAL APPLICATION FORMS [J].
COOREMAN, MP ;
KRAUSGRILL, P ;
HENGELS, KJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) :1506-1509
[7]   METRONIDAZOLE RESISTANCE IN HELICOBACTER-PYLORI [J].
GLUPCZYNSKI, Y ;
BURETTE, A ;
DEKOSTER, E ;
NYST, JF ;
DELTENRE, M ;
CADRANEL, S ;
BOURDEAUX, L ;
DEVOS, D .
LANCET, 1990, 335 (8695) :976-977
[8]  
GLUPCZYNSKI Y, 1990, AM J GASTROENTEROL, V85, P1545
[9]  
GOODWIN CS, 1988, LANCET, V2, P1467
[10]   THE MINIMUM INHIBITORY AND BACTERICIDAL CONCENTRATIONS OF ANTIBIOTICS AND ANTIULCER AGENTS AGAINST CAMPYLOBACTER-PYLORIDIS [J].
GOODWIN, CS ;
BLAKE, P ;
BLINCOW, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 (03) :309-314